Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. The company is headquartered in San Francisco, California and currently employs 54 full-time employees. The company went IPO on 2021-01-08. Its platform allows for the creation of multiple PDTs that are designed to treat patients with CBT, delivered digitally via an app, to address the underlying causes of CMDx. Its lead PDT product candidate, AspyreRx, is a digital behavioral therapeutic delivering CBT for the treatment of a cardiometabolic disease. AspyreRx is a prescription-only digital treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with T2D. The device targets behavior to aid in the treatment of T2D. Its pipeline also includes programs for the treatment of hypertension, hyperlipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH) and chronic kidney disease.
Follow-Up Questions
Better Therapeutics Inc 'in CEO'su kimdir?
Mr. Craig Jalbert 2024 'den beri şirketle birlikte olan Better Therapeutics Inc 'in President 'ıdır.
BTTX hissesinin fiyat performansı nasıl?
BTTX 'in mevcut fiyatı $0.0002 'dir, son işlem günde 0% decreased etti.
Better Therapeutics Inc için ana iş temaları veya sektörler nelerdir?
Better Therapeutics Inc Health Care endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 4 analist Better Therapeutics Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 5 al, 1 tut, 0 sat ve 2 güçlü sat içermektedir
